HRTX Insider Trading Activity and SEC Form 4 Filings
HRTX insider trading summary
No open-market insider purchases or sales of Heron Therapeutics, Inc. (HRTX) have been reported on SEC Form 4 in the past 12 months.
Latest HRTX insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Aug 8, 2025 | Adam Morgan | Director | Buy | $2.6M (1,766,546 @ $1.50) |
| Aug 8, 2025 | Rubric Capital Management LP | 10% Owner | Buy | $3.6M (2,387,225 @ $1.50) |
| Aug 8, 2025 | David Efraim Rosen | 10% Owner | Buy | $3.6M (2,387,225 @ $1.50) |
| Nov 17, 2023 | William P Forbes | EVP, Chief Development Officer | Buy | $27K (25,000 @ $1.09) |
| Nov 16, 2023 | Ira Duarte | EVP, Chief Financial Officer | Buy | $76K (85,000 @ $0.89) |
| Nov 16, 2023 | Craig A Collard | Chief Executive Officer | Buy | $138K (150,000 @ $0.92) |
| Nov 16, 2023 | William P Forbes | EVP, Chief Development Officer | Buy | $47K (50,000 @ $0.94) |
| Jul 21, 2023 | Adam Morgan | Director | Buy | $3.4M (2,486,744 @ $1.37) |
| May 3, 2022 | Kimberly Manhard | EVP, Drug Development | Sell | $7K (1,504 @ $4.76) |
| Dec 21, 2021 | Craig A Johnson | Director | Sell | $2K (250 @ $9.73) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.